Valuation : NEOVACS

Market Cap 4.09K 4.75K 3.87K 3.51K 6.58K 453K 6.62K 45.98K 17.68K 231K 17.82K 17.43K 729K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -233K -190K -173K -324K -22.29M -325K -2.26M -869K -11.34M -876K -857K -35.83M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
1 day-6.25%
1 week-18.92%
Current month-25.00%
1 month-62.50%
3 months-85.00%
6 months-97.27%
Current year-99.66%
1 week 0.28
Extreme 0.28
0.46
1 month 0.28
Extreme 0.28
0.89
Current year 0.28
Extreme 0.28
267
1 year 0.28
Extreme 0.28
4,200
3 years 0.28
Extreme 0.28
32,000,000
5 years 0.28
Extreme 0.28
351,920,000
10 years 0.28
Extreme 0.28
351,920,000
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Director/Board Member - 01/05/2020
Chairman - -
Date Insider Type Main position Quantity % Market Cap. Importance
27/2/21 Sell

Chief Executive Officer

2,505,144 1.3796%
23/2/21 Sell

Chief Executive Officer

6,391,053 3.5196%
23/2/21 Sell

Chief Executive Officer

1,108,947 0.6107%
Change 5-day change 1-year change 3-year change Capi.($)
-6.25%-18.92%-99.99%-100.00% 55.38K
-0.71%-6.35%-2.99%+9.59% 45.48B
+0.21%-2.98%+337.74%+519.55% 43.68B
+1.74%-2.24%+39.82%+20.76% 43.09B
+1.38%-3.28%+6.84%+67.62% 39.4B
-1.44%-5.26%+8.97%+39.76% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+19.75%+110.17% 16.4B
-0.31%-2.78%+10.78%+31.02% 14.24B
+1.93%-3.55%+82.00%+41.17% 13.28B
Average -0.18%-5.11%+44.77%+82.18% 26.48B
Weighted average by Cap. +0.41%-3.67%+74.57%+124.26%

Financials

2023 2024
Net sales 533K 619K 505K 458K 859K 59.15M 863K 6M 2.31M 30.09M 2.33M 2.27M 95.08M 434K 504K 411K 372K 699K 48.12M 702K 4.88M 1.88M 24.48M 1.89M 1.85M 77.35M
Net income -8.74M -10.15M -8.28M -7.5M -14.08M -969M -14.15M -98.33M -37.81M -493M -38.11M -37.28M -1.56B -32.91M -38.2M -31.17M -28.25M -53M -3.65B -53.26M -370M -142M -1.86B -143M -140M -5.87B
Net Debt -237K -274K -224K -203K -381K -26.22M -383K -2.66M -1.02M -13.34M -1.03M -1.01M -42.16M -205K -238K -194K -176K -330K -22.74M -332K -2.31M -887K -11.57M -894K -874K -36.56M
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
16
Date Price Change Volume
11/09/26 EUR 0.3000 -6.25% 55,556
10/09/26 EUR 0.3200 -8.60% 40,202
09/09/26 EUR 0.3501 +2.97% 133,064
08/09/26 EUR 0.3400 -8.11% 14,336
07/09/26 EUR 0.3700 0.00% 9,129
  1. Stock Market
  2. Stocks
  3. ALNEV Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!